-
4 schools share $16M to build cancer equity research centers
The American Cancer Society awarded over $16 million in grants to establish cancer health equity research centers at minority-serving institutions of higher learning across the country, the organization said Feb. 24. -
Hoag selects melanoma program director
Newport Beach, Calif.-based Hoag Memorial Hospital Presbyterian has selected Thomas Wang, MD, PhD, to serve as medical director of its melanoma/advanced skin cancer program. -
City of Hope receives $4.9M stem cell research grant
Los Angeles-based City of Hope was awarded a $4.9 million grant for its department of stem cell biology and regenerative medicine, the cancer research group said Feb. 22. -
Atlantic Health System taps new hematology director
Morristown, N.J.-based Atlantic Health System named Mohamad Cherry, MD, medical director of its hematology and cellular therapy programs, it said Feb. 23. -
Yale, National Brain Tumor Society launch research consortium
Yale Cancer Center is partnering with the National Brain Tumor Society to launch a flagship research initiative focused on DNA damage, the cancer center said Feb. 22. -
Karmanos Cancer Institute to pilot virtual platform
The Barbara Ann Karmanos Cancer Institute in Detroit is collaborating with Lifeguard Health Networks to pilot a digital care platform for cancer patients. -
6 oncologists on the move
These six oncologists joined new practices or received new appointments over the last few weeks. -
9 ways to get screening rates to pre-pandemic levels, per American Cancer Society
The American Cancer Society's National Consortium for Cancer Screening and Care outlined nine recommendations to bring screening rates back to pre-pandemic levels in a Feb. 16 report. -
4 recent moves from MD Anderson
Here are five moves reported by Becker's about the University of Texas MD Anderson Cancer Center since Jan. 10: -
Phase 3 trial results promising for antibody drug treating HER2 breast cancer type
AstraZeneca and Daiichi Sankyo's Enhertu breast cancer drug significantly helped patients with HER2-low metastatic breast cancer in its phase 3 clinical trial, AstraZeneca said Feb. 21. -
Yale Cancer Center adds $1.5M to hematology fellowship
Yale Cancer Center invested $1.5 million to improve its hematology/oncology fellowship program, it said Feb. 18. -
Rutgers Cancer Institute names director of investigational therapeutics program
Rutgers Cancer Institute of New Jersey named Sanjay Goel, MD, director of its investigational therapeutics program, it said Feb. 16. -
MD Anderson receives $31.7M from research institute
The University of Texas MD Anderson Cancer Center was awarded $31.7 million from the Cancer Prevention and Research Institute of Texas, the center said Feb. 16. -
MD Anderson renews Banner Health partnership
The University of Texas MD Anderson Cancer Center extended its partnership with Phoenix-based Banner Health for another 10 years, the cancer center said Feb. 15. -
COVID-19 driving up late-stage cancer diagnoses, small study suggests
Delayed screenings as a result of the COVID-19 pandemic have led to later-stage cancer diagnoses, a small study published Feb. 15 in JAMA Network Open suggests. -
4 recent leadership changes at Yale Cancer Center
Yale Cancer Center recently made several leadership changes. -
Mayo Clinic model predicts therapy benefits for gastric cancer patients
The use of genomic sequencing to predict the likelihood that gastric cancer patients will benefit from chemotherapy or from immunotherapy has been validated by findings in a study published Feb. 9 in Nature Communications. -
Viewpoint: We don't have to wait for the 'cancer moonshot' to save more lives
While the White House's revival of the Cancer Moonshot — a program to cut cancer deaths by 50 percent over the next 25 years — is an ambitious and important goal, more can be done today to benefit cancer patients, according to Edward Abrahams, PhD. -
5 recent cancer study findings
Recent cancer research has findings on cancer trends among African Americans and the impact of COVID-19 on cancer research. -
Yale Cancer Center names first deputy director of clinical affairs
Yale Cancer Center appointed Roy Herbst, MD, its inaugural deputy director of clinical affairs at the center and New Haven, Conn.-based Smilow Cancer Hospital, the center said last week.
Page 43 of 50